WallStSmart

InnovAge Holding Corp (INNV)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 7793% more annual revenue ($72.25B vs $915.37M). LLY leads profitability with a 35.0% profit margin vs 0.7%. LLY trades at a lower P/E of 34.3x. LLY earns a higher WallStSmart Score of 78/100 (B+).

INNV

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 4.5Value: 5.7Quality: 6.0
Piotroski: 5/9Altman Z: 1.74

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INNVUndervalued (+45.5%)

Margin of Safety

+45.5%

Fair Value

$15.02

Current Price

$7.96

$7.06 discount

UndervaluedFair: $15.02Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INNV0 strengths · Avg: 0/10

No standout strengths identified

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$862.01B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.8%10/10

Earnings expanding 169.8% YoY

Areas to Watch

INNV4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.744/10

Distress zone — elevated risk

Market CapQuality
$1.08B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
1.2%3/10

ROE of 1.2% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
34.3x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
33.3x2/10

Trading at 33.3x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : INNV

Revenue growth of 14.7% demonstrates continued momentum.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : INNV

The primary concerns for INNV are Altman Z-Score, Market Cap, Return on Equity. A P/E of 159.2x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Key Dynamics to Monitor

INNV profiles as a value stock while LLY is a growth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.50 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 31/100), backed by strong 35.0% margins and 55.5% revenue growth. INNV offers better value entry with a 45.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InnovAge Holding Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

InnovAge Holding Corp. The company is headquartered in Denver, Colorado.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?